Folate levels in hepatocellular carcinoma patients with portal vein thrombosis

• Published in: BMC Gastroenterology 2020, Vol.20 (1)
• Main Authors: Malaguarnera, Giulia, Catania, Vito Emanuele, Latteri, Saverio, Borzì, Antonio Maria, Bertino, Gaetano, Madeddu, Roberto, Drago, Filippo, Malaguarnera, Michele
• Format: Report
• Language: English
• Subjects: Care and treatment; Complications and side effects; Development and progression; Folic acid; Health aspects; Hepatocellular carcinoma; Venous thrombosis
• ISSN: 1471-230X; 1471-230X
• DOI: 10.1186/s12876-020-01525-3

Portal vein thrombosis (PVT) occurs frequently in hepatocellular carcinoma (HCC) and is often diagnosed in the course of a routine patient evaluation and surveillance for liver cancer. The purpose of this study is to investigate the relationship between folate status and portal vein thrombosis. HCC with PVT patients were 78, HCC without PVT were 60 and control subjects were 70 randomly selected. We evaluate serum and red blood cellular folate, homocysteine, alpha fetal protein cholesterol, triglycerides, prothrombin time. HCC patients with PVT showed lower levels of serum folate, respect HCC patients without PVT, with an average difference of 1.6 nmol/l p < 0.01 (95% CI - 2.54 to - 0.66), red cell folate 33.6 nmol/l p < 0.001 (95% CI - 43.64 to - 23.55) and albumin 0.29 g/dl p < 0.001 (95% CI - 0.42 to - 0.15); PVT patients displayed higher levels of bilirubin 0.53 mg/dl p < 0.001 (95% CI 0.23 to 0.78), INR 0.91 p < 0.001 (95% CI 0.72 to 1.09), [gamma]GT 7.9 IU/l (95% CI 4.14 to 11.65) and homocysteine 4.6 [mu]mol/l p < 0.05 (95% CI 0.32 to 8.87) The low folate concentration and higher levels of homocysteine are associated with the loss of antithrombotic function, and with a more aggressive course of HCC and with a higher change of complications related to portal vein thrombosis